<DOC>
	<DOCNO>NCT02494024</DOCNO>
	<brief_summary>This study evaluate safety tolerability ( maximum tolerate dose ( MTD ) within specify dose range ) single intravenous ( IV ) infusion C2N-8E12 patient progressive supranuclear palsy ( PSP ) .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics C2N-8E12 Subjects With Progressive Supranuclear Palsy</brief_title>
	<detailed_description>This study evaluate safety , tolerability , pharmacokinetics , maximum tolerate dose ( within dose range ) intravenous ( IV ) infusion C2N-8E12 32 patient progressive supranuclear palsy ( PSP ) . Four sequential cohort receive increase single dos either C2N-8E12 placebo . Out every 4 patient enrol 3 patient receive drug 1 receive placebo . Study participant follow minimum 2 month post-treatment monitor safety , tolerability , pharmacokinetics , immunogenicity C2N-8E12 .</detailed_description>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<criteria>Key Meets NINDSSPSP possible probable criterion modify NNIPPS AL108231 clinical trial Brain MRI Screening consistent PSP ; Stable medication Parkinsonism least 2 month prior Screening ; Agree use protocol specify method contraception . Key Signs progressive neurological disorder well meet criteria type neurological disorder PSP ; Currently biologic immunomodulatory therapy ; Subjects reside skilled nursing dementia care facility ; Diagnosis significant unrelated neurological psychiatric disorder could account cognitive deficit ; Untreated major depression baseline evaluation , base clinical judgment result geriatric depression scale ; Unable tolerate MRI scan Screening contraindication MRI ; Any contraindication unable tolerate lumbar puncture Screening , include use anticoagulant medication .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>PSP</keyword>
	<keyword>C2N-8E12</keyword>
	<keyword>tauopathy</keyword>
	<keyword>Progressive Supranuclear Palsy</keyword>
	<keyword>Steele Richardson Olszewski Syndrome</keyword>
	<keyword>Humanized anti-tau antibody</keyword>
</DOC>